Title: Cangrelor
CAS Registry Number: 163706-06-7
CAS Name: N-[2-(Methylthio)ethyl]-2-[(3,3,3-trifluoropropyl)thio]-5¢-adenylic acid monoanhydride with (dichloromethylene)bis[phosphonic acid]
Additional Names: N6-(2-methylthioethyl)-2-(3,3,3-trifluoropropylthio)-b,g-dichloromethylene ATP
Manufacturers' Codes: AR-C69931XX
Molecular Formula: C17H25Cl2F3N5O12P3S2
Molecular Weight: 776.36
Percent Composition: C 26.30%, H 3.25%, Cl 9.13%, F 7.34%, N 9.02%, O 24.73%, P 11.97%, S 8.26%
Literature References: Specific P2Y12 purinoceptor antagonist; inhibits ADP-induced platelet aggregation. Prepn: A. H. Ingall et al., WO 9418216 (1994 to Fisons); eidem, US 5721219 (1998 to Astra); and in vivo antithrombotic activity: idem et al., J. Med. Chem. 42, 213 (1999). In vivo antithrombotic effects in canine arterial thrombosis: J. Huang et al., J. Pharmacol. Exp. Ther. 295, 492 (2000). Mechanism of action study: A. Ishii-Watabe et al., Biochem. Pharmacol. 59, 1345 (2000). Clinical safety assessment and evaluation in acute coronary syndromes: R. F. Storey et al., Thromb. Haemostasis 85, 401 (2001); in angina pectoris and non-Q-wave myocardial infarction: F. Jacobsson et al., Clin. Ther. 24, 752 (2002). Clinical pharmacodynamics compared with clopidogrel: R. F. Storey et al., Platelets 13, 407 (2002). Review of clinical development: S. C. Chattaraj, Curr. Opin. Invest. Drugs 2, 250-255 (2001).
Derivative Type: Tetrasodium salt
CAS Registry Number: 163706-36-3
Manufacturers' Codes: AR-C69931MX
Molecular Formula: C17H21Cl2F3N5Na4O12P3S2
Molecular Weight: 864.29
Percent Composition: C 23.62%, H 2.45%, Cl 8.20%, F 6.59%, N 8.10%, Na 10.64%, O 22.21%, P 10.75%, S 7.42%
Properties: Freely sol in water.
Therap-Cat: Antithrombotic.
Keywords: Antithrombotic.
Cannabinol Cantharidin Capobenic Acid Capravirine Caprenin

CAS number 163706-06-7 YesY
PubChem 9854012
ChemSpider 8029718 N
IUPHAR ligand 1776
Jmol-3D images Image 1
Molecular formula C17H25Cl2F3N5O12P3S2
Molar mass 776.36 g mol−1
 N (verify) (what is: YesY/N?)
Except where noted otherwise, data are given for materials in their standard state (at 25 °C (77 °F), 100 kPa)
Infobox references

Cangrelor is a P2Y12 inhibitor under investigation as an antiplatelet drug[1] for intravenous application. Some P2Y12 inhibitors are used clinically as effective inhibitors of adenosine diphosphate-mediated platelet activation and aggregation.[1] Unlike clopidogrel (Plavix), which is a prodrug, cangrelor is an active drug not requiring metabolic conversion.

Poor interim results led to the abandonment of the two CHAMPION clinical trials in mid-2009.[2] The BRIDGE study, for short term use prior to surgery, continues.[3] The CHAMPION PHOENIX trial was a randomized study of over 11,000 patients published in 2013. It found usefulness of cangrelor in patients getting cardiac stents. Compared with clopidogrel given around the time of stenting, intravenous ADP-receptor blockade with cangrelor significantly reduced the rate of stent thrombosis and myocardial infarction.[4] Reviewers have questioned the methodology of the trial.[5]